4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
CytoMed Therapeutics Limited (GDTC) operates in the Biotechnology industry and is headquartered in Singapore, Singapore with about 42 employees. Its market capitalization is roughly $11 million. In the fiscal year ended 2025-12-31, GDTC reported $0M in revenue and ($4M) in net income.
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore.
Interactive charts & full statements → Open the GDTC valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Gross Profit | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($4M) | ($3M) | ($4M) | ($2M) | — |
| Net Income | ($4M) | ($2M) | ($4M) | ($3M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | $0M | $0M | $0M | $0M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $8M | $10M | $12M | $5M | — |
| Total Liabilities | $1M | $1M | $1M | $5M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GDTC viewer.
About TickerBase · Data methodology & sources